Assessment of chloroquine single dose treatment of malaria due to Plasmodium vivax in Brazilian Amazon
Rev. Inst. Med. Trop. Säo Paulo
;
45(6): 327-331, Nov.-Dec. 2003. tab, graf
Article
in English
| LILACS
| ID: lil-353984
ABSTRACT
Malaria regions of the Amazon basin have been characterized by difficult access and non-compliance of the patients to treatment. In an attempt to assess the schizonticide efficacy of chloroquine in a single dose of 600 mg, the authors realized a double-blind, placebo-controlled trial in 132 outpatients with vivax malaria. Patients were distributed into two groups group CPLA, given chloroquine 600 mg (single dose) on the first day of treatment, and two doses of placebo on second and third days. Group CHLO, given chloroquine 600 mg on first day and 450 mg on second and third day. Geometric means of the parasite density during the follow-up was similar in both groups. No differences were observed in the parasitological cure between the two groups (p = 0.442). There was clinical and parasitological efficacy in treatment of patients given a single-dose of chloroquine. This suggests that its restricted use could be indicated in remote areas of Brazilian Amazon Region, nevertheless the inadequate response of three patients indicates the need for further studies.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Plasmodium vivax
/
Chloroquine
/
Malaria, Vivax
/
Antimalarials
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Animals
/
Female
/
Humans
/
Male
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Rev. Inst. Med. Trop. Säo Paulo
Journal subject:
Tropical Medicine
Year:
2003
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Centro de Ensino Superior do Pará/BR
/
Instituto Evandro Chagas/BR
Similar
MEDLINE
...
LILACS
LIS